

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12Q 1/68, 1/70, G01N 33/566, 33/58</b>		A1	(11) International Publication Number: <b>WO 98/53100</b> (43) International Publication Date: 26 November 1998 (26.11.98)				
(21) International Application Number: PCT/IT98/00130 (22) International Filing Date: 22 May 1998 (22.05.98)  (30) Priority Data: RM97A000304 22 May 1997 (22.05.97) IT		(81) Designated States: AU, CA, CN, IL, JP, KR, MX, NO, NZ, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>					
(71) Applicant ( <i>for all designated States except US</i> ): ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P.ANGELETTI S.P.A. [IT/IT]; Via Pontina Km. 30,600, I-00040 Pomezia (IT).  (72) Inventors; and (75) Inventors/Applicants ( <i>for US only</i> ): CORTESE, Riccardo [IT/IT]; Via Massimiliano Massimo, 16, I-00144 Roma (IT). MONACI, Paolo [IT/IT]; Via Appia Nuova, 420, I-00181 Roma (IT).  (74) Agents: GILBERTO, Tonon et al.; Società Italiana Brevetti S.p.A., Piazza di Pietra, 39, I-00186 Roma (IT).							
(54) Title: METHOD BASED ON THE USE OF BACTERIOPHAGES FOR THE DETECTION BIOLOGICAL MOLECULES IN BIOLOGICAL SAMPLES							
(57) Abstract <p>The present invention refers to a method that allows the use of filamentous bacteriophages to detect the presence of molecules of interest in biological samples. It consists of a series of combined operations, which are drawn up and defined according to the characteristics of the phages employed. These have, exposed on the surface of the capsid, at least one molecule, generally but not exclusively of proteic nature, capable of binding at least one molecule of interest present in said biological sample. Detection of the presence of said molecule takes place, according to the method of the invention, using the association between the molecule exposed on the surface of the phage and the genome of the phage itself. The ability to form specific complexes typical of the molecule exposed on the capsid, does enable formation of phage-molecule of interest complexes, which can be detected by means of amplification of known sequences in the phage DNA. The method according to the invention is extremely sensitive and can be used in particular for diagnostic and prognostic purposes.</p>							
<table border="1" style="width: 100%; text-align: center;"> <tr> <td style="width: 50%;"><b>C15 C17 C22</b></td> <td style="width: 50%;"><b>N57 N60</b></td> </tr> <tr> <td style="height: 150px;"></td> <td style="height: 150px;"></td> </tr> </table>				<b>C15 C17 C22</b>	<b>N57 N60</b>		
<b>C15 C17 C22</b>	<b>N57 N60</b>						

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD BASED ON THE USE OF BACTERIOPHAGES FOR THE DETECTION BIOLOGICAL MOLECULES IN BIOLOGICAL SAMPLES

DESCRIPTION

The present invention refers to a method for 5 detection of the presence of molecules of interest in biological sources. This responds to a need common to many areas of scientific research. In fact, the ability to identify the presence in biological samples of molecules, associated for example with clinical 10 pathologies, has always represented an important objective for research, in particular in the field of medicine.

The bio-medical field is without doubt the main (although not the only) field in which this method is 15 applied. In fact the inventions relating to methods with this purpose have been proposed with the aim of reaching an increasingly high level of sensitivity in detection, in particular at a diagnostic level.

The bio-chemical instrument most frequently used to 20 detect the presence of specific molecules in cell or tissue extracts are antibodies, because of their extreme sensitivity and high binding specificity.

When an interaction with the molecule of interest 25 occurs in these methods, it is highlighted using markers linked to the antibodies themselves, for example fluorescent substances, proteins with enzymatic activity, or radioactive markers.

The detection capacity of these markers has in any 30 case been found to be considerably enhanced by the use of so-called signal amplification methods. These make it possible to obtain a stronger detection signal, for example by joining the marker not to the antibody used for specific recognition (primary antibody), but to a second antibody capable of binding the first one 35 (secondary antibody). A number of methods have been developed using secondary antibodies, to which marker molecules are covalently bonded, for example fluorescent

-2-

substances such as fluorescein or rhodamin, proteins with enzymatic activity such as alkaline phosphatase or horseradish peroxidase, in case of detection using electron microscope ferritin or colloidal gold spheres are also used.

Alternative amplification systems make use of the high binding affinity of molecules such as Biotin (a small, water-soluble vitamin) and streptavidin (bacterial protein), or those between lecithins (proteins capable of 10 recognising and binding specific saccharide residues) and molecules such as glycoproteins, glycolipids or proteoglycans.

An extremely wide series of variations on this theme is possible, including those allowing creation of a 15 network of markers, capable of considerably amplifying the detection signal. In any case all these methods are connected to the use of antibodies as molecules capable of specific identification of a target molecule, and they also have a sensitivity level that is limited by the 20 concentration of target molecules.

The latter limitation has been overcome by methods drawn up more recently, which are based on the application of PCR (Polimerase Chain Reaction) techniques for this purpose, used here in place of the detection 25 enzymes. These methods, in fact, are again based on the use of monoclonal antibodies against a specific ligand, which in this case, however, are not physically coupled to proteins, but to polynucleotides with a known sequence.

This makes it possible to perform subsequent 30 detection by amplification of the known DNA sequence, which is effectively achieved using a polymerase chain reaction (PCR) (V. Ruzicka et al, 1993; T. Sano et al, 1992; H. Zhou et al, 1993).

This method, known as immuno PCR, makes it virtually 35 possible to detect even a single antibody bound to the target molecule. In spite of the considerable improvement

- 3 -

in sensitivity, these methods present a series of problems, among which the direct association of polynucleotides and antibodies, and the resulting high background due to the inevitable interference by the 5 polynucleotide during binding of the antibody to the molecule of interest.

Furthermore, given that the specificity and yield of the amplification reaction depend on the temperature at which the reagents are mixed, it is possible to obtain, 10 if assembly of the PCR reaction takes place at temperatures lower than those considered optimum for hybridisation of the primers, non-specific hybridisation products.

15 Currently this problem has been solved by addition to the amplification reaction of an essential reagent, only after the system has reached the temperature allowing specific hybridisation of the "Hot Start" primers. This procedure is achieved by mechanically separating a reagent (D.E. Birch et al, 1996), or by 20 using antibodies to block the enzymatic activity of DNA polymerase (J. Cheng et al, 1996).

Recently, a PCR method performed on cells has also 25 been developed, known as *in situ* PCR (G.J.Nuovo, 1994), in which amplification follows an *in situ* hybridisation reaction. According to this method the DNA template and the primers are kept physically separate until the moment of cell lysis, with the advantage of avoiding any non-specific hybridisation reactions (EP 524808 Hoffmann La Roche Inc.).

30 Furthermore, there are a series of patents all relating to new diagnostic methods that are supposed to overcome many of the problems typical of current methods, and consequently improve amplification of the response signal. These have as their subject matter various 35 methods, such as the use of PCR associated with the discovery of particular proteins (WO9421676); the use of genetically engineered hybrid enzymes conjugated to

-4-

ligands, for example epitopes of the virus HIV-1 (WO942636); the use of viral epitopes generated from nucleic acids combined with proteins binding the antigen (WO9406934); the use of parts of viral cDNA, for example taken from HCV, to express a viral epitope connected to a control sequence and a monoclonal antibody directed against the epitope. In the latter case the cDNA region of interest allows cross-reference controls to be carried out between the antibody response and that resulting after hybridisation with the DNA (EP388232).

Another patent, on the other hand, has as its subject the construction of a library of antigenic determinants, obtained by digestion with DNAase-I, of the genome of a virus, for example HIV, which is followed by expression of these fragments obtained by means of a suitable vector, and subsequent selection of said expression products by the use of antibodies (EP373070).

In this context the value of the present invention consists in its having as its subject matter an extremely versatile method, that can be used in widely differing situations and for widely differing purposes, according to methods that enable various problems present in the state of the art to be overcome.

The method according to the invention does not in fact presuppose the production of specific antibodies, but the use of recombinant filamentous phages exhibiting onto the capsid any molecule capable of interacting with the molecule of interest in the sample to be examined.

It also allows, when a phage exhibiting a suitable molecule is available, detection of the presence of any type of molecule of interest (not merely amino acids), even if the molecule in question is present in infinitesimal amounts, in biological samples of various origin (not only in samples taken from the human body or from the body of animals, but also in samples of other types, for example water, drinks or food substances). Combination of the operations forming the subject of the

- 5 -

invention is also articulated so as to eliminate the risk of non-specific association between DNA and reagents and the consequent background, which can compromise the clarity of the result.

5 These advantages are a consequence of the fact that the DNA used to detect by PCR is not directly exposed to the reagents, but is contained inside the recombinant phages employed.

10 The presence of the proteic capsid wrapping actually prevents the DNA used for subsequent detection from interfering during the binding reaction between the ligand molecule (the one exposed on the capsid) and the receptor molecule (the one of interest in the sample).

15 Following this, after interaction between the ligand molecule and the receptor molecule, suitable washing operations are carried out to eliminate the phages that have not bound by specific interaction to the receptor. Finally, the nucleotide sequences of the phage DNA are 20 amplified by adding the necessary reagents according to a process that avoids the insurgence of non-specificity. In fact, the DNA to be amplified remains protected during the initial stages by the proteins of the phage capsid, which are only denatured at the moment in which the polymerisation reaction starts.

25 A further advantage derives from the fact that the basic recombinant phagemid, used to construct the receptor phages, is essentially secreted by E. Coli as a particle containing single-strand DNA. It is, in fact, known from the state of the art that the use of PCR on a 30 single-stranded DNA template gives better results than that carried out on double-strand DNA.

The invention will be further clarified with reference to the annexed figures.

35 Figure 1 shows the result of amplification of the DNA of a phage P787, exhibiting on the surface of the capsid a peptide capable of binding anti-HCV antibodies. Visualisation is by UV fluorescence on agarose gel

-6-

containing ethidium bromide. M is a reference to molecular weights obtained by hydrolysing the plasmid DNA pUC19 with the restriction enzyme Hinf I.

5 Figure 2 shows the result of amplification of the DNA of a phage mix after incubation with C17 and C22 serum from patients whose serum contains anti-HCV antibodies. Visualisation is by UV fluorescence on agarose gel containing ethidium bromide. PC89 is the non-recombinant phage with which the phage library was 10 constructed, used here as a negative control.

15 Figure 3 shows the result of amplification of the DNA of the same phage mix used in figure 2, after incubation with N57 and N60 serum from two volunteers whose serum does not contain anti-HCV antibodies, and who are therefore considered negative controls. Visualisation is by UV fluorescence on agarose gel containing ethidium bromide. PC89 is a negative control phage described above in example 1. M is a reference to molecular weights obtained by hydrolysing the plasmid DNA pUC19 with the 20 restriction enzyme Hinf I.

25 The subject matter of the present invention is a method for determination and measurement of the presence of certain molecules of interest, also indicated in this context as receptor molecules, on the basis of their ability to be specifically recognised at least by a certain molecule, here indicated as the ligand molecule, which is exposed on the phage capsid.

30 It is necessary to underline how in the present description the concepts of ligand molecule and receptor molecule are strictly interdependent, and strictly bound to the specific working context. As a result of this, a molecule exposed on the surface of the capsid is defined 35 "ligand" solely on the basis of its ability to specifically bind to the molecule presumed to be present in the sample, the presence or concentration of which is to be measured, which is therefore defined "receptor", and vice versa.

In the present invention, any molecule obtained from sources such as biological fluids, surfaces of cells or tissues, is considered to be a "receptor" if its presence can be identified by means of interaction with a specific 5 "ligand" as defined above. For example, antibodies capable of recognising clearly identified antigens (such as viral antigens, tumoural antigens or antigens present in normal tissues), or antigens whose precise molecular nature has not yet been identified, belong to the 10 category of "ligands", although they are not alone in that category. In this case, these antigens will be considered to be "receptors". These definitions are connected, for example, to the case in which the presence 15 and/or concentration of these antigens in the biological fluids or on the surfaces of cells and tissues under examination is an indication with diagnostic value. However, in accordance with the method according to the 20 present invention the antigens themselves can be used as "ligands" in the case that the receptor molecule of interest, the presence or concentration of which it is necessary to determine, is made up of antibodies.

In the same way it is possible to consider "receptors", if of interest, even specific receptors present on the membrane of single cells or of the cells 25 in tissues, along with the soluble receptors present in biological fluids, which will be detected in this case by the molecules capable of binding with them specifically, acting as "ligands". Naturally it is possible to invert the relationship when the molecules of interest are no 30 longer made up of membrane receptors (which in this case will act as "ligands"), but of their specific ligands (which in this case will be considered "receptors").

It can thus be understood that any molecule whose presence in the sample under examination is considered to have a diagnostic and/or prognostic value (after having 35 ascertained its association with the appearance of a specific pathology), or is of interest for whatever

- 8 -

purpose, can be included in the category "receptors".

The many applications of this method are quite evident, particularly in the medical and veterinary field, but also in other fields, for example food and the environment.

This method has been drawn up following verification by the inventors of the possibility of using filamentous bacteriophages, either recombinant or non-recombinant, to detect interaction between a "ligand" and a receptor molecule present in a sample, even at extremely low concentrations, by amplification of specific nucleotide sequences present in the phage genome and physically or genetically associated with the "ligand".

In brief, the method according to the invention can be applied every time it is possible to identify:

A) a receptor molecule or a homogeneous class of "receptors" forming a group, the presence of which in biological fluids or on the surfaces of cells or tissues is correlated with a certain pathology or is in any case of considerable interest, for example for diagnostic purposes;

B) a "ligand" or a class of "ligands", for example of polypeptide type, whose structure allows them to be exposed on the capsid of bacteriophages, preserving the ability to bind specifically to the receptor molecule.

The subject matter of the present invention is therefore a method based essentially on the following operations:

a) immobilising the molecules of interest without destroying the ability to interact with the molecules exposed on the surfaces of the phage;

b) causing a molecule of interest, immobilised as above, to bind specifically with at least one of the recombinant filamentous bacteriophages, which have internally a single-strand DNA molecule whose sequence is at least partially known, and exposing on the surfaces of the capsid at least one molecule capable of binding

- 9 -

specifically to at least one molecule of interest present in the biological sample;

c) separating the molecule-bacteriophage complexes obtained in this manner from the reaction mixture;

5 d) washing to remove the complexes generated by non-specific interaction between molecule and bacteriophage;

e) adding the reagents to carry out the operation described under g) below;

10 f) lysating the proteins forming the protein capsid of the bacteriophages selected in this way;

g) amplifying the DNA obtained as above by polymerase chain reaction (PCR);

15 h) detecting the DNA amplified as above, for example using conventional methods.

15 The methods for detecting the amplified DNA can be for example electrophoresis on agarose gel in the presence of ethidium bromide, capillary electrophoresis, hybridisation to specific radioactively marked or luminescent probes.

20 In particular the operation indicated under g), that is to say amplification of the phage DNA, is carried out using PCR techniques, using a pair of oligonucleotides of which at least one is complementary to a known sequence of the phage DNA. Furthermore, it has been found that 25 using a protocol for lysis of the phage capsid proteins at the temperature in which denaturation of the DNA takes place, which usually falls within the range of 93-96°C, contact between primers and DNA template takes place at the same temperature, and thus a "Hot Start" is obtained 30 for the PCR, with the consequent virtual elimination of non-specific reaction products.

An important application for this method is when the molecules of interest are antibodies.

35 A further specific application is when immobilisation of the molecules of interest is carried out in the solid phase, and in this case when it is in turn achieved by passive adsorption and/or using

- 10 -

antibodies specific for the molecules themselves.

In any event, immobilisation can also be achieved by use of bacteria or of at least one of the bacterial proteins selected from the group comprising protein A of *Staphylococcus Aureus*, protein G of group C *Streptococci* and any other bacterial protein capable of binding animal immunoglobulins.

Further applications of the method, of particular interest, are those in which the bacteriophages used exhibit on the surfaces of the capsid viral antigens, auto-antigens (antigens that can be present in the animal which is the source of the biological fluids), allergens, cell membrane receptors, parts of said molecules or oligopeptides capable of mimicking the presence thereof in the biological fluids under examination, as well as specific cell membrane receptors or peptides deriving therefrom, or ligands of amino acid type whose receptor is present in the fluids to be tested.

Among the fundamental aspects of this method is first of all the fact that the instruments used for detection are always filamentous bacteriophages, generally of recombinant type M13, f1 or fd, which make it possible to expose on the surfaces of the capsid one or more molecules, preferably of amino acid type, which act as "ligands", capable of interacting specifically with the "receptor" that is to be tested. This forms a first element of originality, given that there is no longer direct use of ligand molecules, but of phages containing suitably selected natural "ligands", their parts or mimes.

The present invention distinguishes itself from other detection methods described in the past, such as immuno-PCR, in which an antibody is artificially bound to a polynucleotide molecule with a known sequence used as a probe, in the very fact that in this invention the genetic information contained inside the phage is used to determine the presence of a molecule of interest.

- 11 -

Furthermore, the ability to use different phages simultaneously make it possible to detect simultaneously different parts of a molecule of interest, or even a number of molecules of interest.

5 However, the main characteristic is above all the association of the "ligand" exposed on the surfaces of the phage and the phage DNA, used for detection by PCR. This can be made up of the genetic information coding for the "ligand", but also more generally of any nucleotide sequence in the phage genome.

10 As a result of this the method of the invention also makes it possible to select the nucleotide sequences associated with the "ligand" to be used for detection, so as to increase the specificity and decrease the 15 amplification reaction time. In effect, to achieve a PCR reaction, the sequence of the oligonucleotide primers, the duration and the temperature at which each incubation takes place, and the number of cycles in each reaction, 20 can be pre-selected at this time so as to obtain extremely rapid and highly specific amplification.

25 In effect, by its nature, the genetic information present inside the phage and used for detection is particularly prone to be amplified using current PCR methods, which make it possible to highlight the presence of even a single DNA molecule in the reaction tube. The sensitivity that can be obtained using the polymerase chain reaction cannot easily be reached using other detection methods currently in use.

30 A further advantage resulting from this is closely connected to the fact that the oligonucleotide probes used for amplification can be designed so as to give specific amplification of a particular sequence present in a phage, even in the presence of the DNA from other 35 phages that do not include it. For example it is possible to design the probes so as to amplify only the DNA of phages containing a specific insert (for example the one coding for the molecule that acts as a "ligand" when

- 12 -

exposed on the capsid), even in the presence of the DNA of phages that do not contain this insert, or that contain inserts with a different sequence. The most direct consequence of this is that it is possible to react the receptor molecule (or the receptor molecules) under examination with a mixture of different phages, and identify the bond with each single type of phage even in the presence of the others.

Furthermore, the fact that the DNA is contained inside the proteic capsid enables one of the limitations in detection specificity typical of PCR methods to be overcome. This limitation is the need to place the DNA template in contact with the amplification probes at a relatively low temperature, according to the sequence of the two primers. When the temperature is raised to start the first amplification cycle, part of the DNA remains complexed to the probe and this results in a non-specific elongation of the probe itself on the DNA template. Various methods have been proposed to remedy this problem (4, 5). The method of the present invention, as mentioned above, enables the problem to be solved brilliantly, making use of the fact that a naturally encapsidated DNA is used, which is therefore protected from contact with the specific probes until the time of lysis of the capsid. In this regard, an extremely high specificity can be obtained merely by perfecting the method and using a thermal lysis protocol that allows contact between the DNA and the specific probe only at high temperature.

In this manner, which is achieved in the embodiment rather simply and is extremely practical, it is possible to obtain what in technical terms is known as a "Hot Start" for the PCR.

Up to this point a general description has been given of the present invention. With the aid of the following examples, a more detailed description of specific embodiments will now be given, with the aim of giving a clearer understanding of the objects,

- 13 -

characteristics, advantages and operating methods of the invention. These examples are merely illustrative, and in no way limit the scope of the present invention, which is defined in the enclosed claims.

5        EXAMPLE 1

Method for detection, in the serum of patients, of the presence of antibodies specific for the antigens of human hepatitis C virus (HCV)

10       The following method was used according to the invention:

15       Amounts of human goat-anti-IgG immunoglobins, specific for the Fc portion, were absorbed in the wells of a polycarbonate plate made up of 96 wells, currently in use for PCR methods (Thermowell-II™ type 6509 produced by Costar). After incubation the plate was washed with a saline phosphate buffer, and the residual absorption sites were blocked by incubation in a buffer in which powdered skimmed milk was re-suspended (as described in the literature). The following were 20 dispensed into the wells on the plate prepared in this way : 1) amounts of the human serum being tested, diluted to various levels; in this example the human serum types C17 and C22 from patients infected with HCV and containing anti-HCV antibodies was used. N57 and N60 were 25 serum types obtained from apparently healthy individuals in which no anti-HCV antibodies were found. Amounts of these serums were mixed with a phage of non-recombinant type, which acts as a non-specific carrier. A recombinant phage 2A was also added, that can be amplified in the PCR reaction but that does not exhibit the specific ligand on the capsid, in this example peptides capable of binding 30 human anti-HCV antibodies; and alternatively 2B the HCV-specific phage P787.

35       After incubation at 37° for 90 minutes, the plate was emptied and washed with phosphate buffer to remove all the recombinant phages that were not specifically bound. A mixture was then added to each well, containing

- 14 -

the DNA probes specific for amplification, the polymerase Taq, triphosphate dioxynucleotides, in a buffer suitable for the PCR reaction.

5 The plate was transferred to a thermal incubator for PCR and the process continued with reaction cycles that started with heating for 5 minutes at 95°C. This passage is particularly important because it is only at this temperature that lysis of the phage proteins takes place, and consequently contact of the specific probes with the 10 DNA to be amplified. The PCR reaction this starts at high temperature (hot start) and continues with 25 cycles of 10 seconds at 94°C and 10 seconds at 72°C. The reaction terminates with incubation at 72°C for 2 minutes.

15 The DNA of phage P787 amplified in this way is highlighted by electrophoresis on agarose gel containing ethidium bromide, as shown in the specific example of figure 1.

EXAMPLE 2

20 Use of a composition of phages to diagnose the presence of anti-HCV antibodies in the serum of patients

25 A composition of a number of specifically selected phages, each of which mimics different proteic regions of the human hepatitis C virus, was used to diagnose the presence of anti-HCV antibodies in a serum. As the phages can be distinguished according to the sequence they carry, but also, more simply, by the length of the insert, it is possible to observe amplification of DNA fragments of different lengths on the agarose gel, according to the dimensions of the phage DNA insert.

30 In this example it is shown how, using a mixture of phages, it is possible to obtain a response on agarose gel as described in example 1. The example shows that a mixture of phages is more predictive than use of a single phage.

35 It is surprising that in a serum it is possible to identify antibodies for different antigens, and that the amplification response is specific. The result shown in

- 15 -

figure 2 and figure 3 consists however of a response that can be analysed by electrophoresis as described above for example 1.

EXAMPLE 3

5    Method for detection in vitro of human anti-IL-6 antibodies

10    A method is described in which the receptor for IL-6 is immobilised on a plate and phages expressing IL-6 are used to detect the presence thereof in extra-cellular culture mediums.

15    The human cDNA coding for hIL-6 was fused to the amino-terminal end of gene III of a phagemid obtained from M13 as described in the literature. The recombinant hIL-6/M13-pIII phage can be used to detect the presence of the human interleukin 6 receptor. In the art a description has already been given of how it is possible to select a phage expressing hIL-6 that is capable of binding in vitro both hIL-6/R and anti-hIL-6 antibodies as described in the literature. We have proved that 20    recognition is possible and more effective if the method described in the present invention is used.

25    On a solid support, for example a plastic bead, 1 $\mu$ g of monoclonal anti-hIL-6 antibodies were fixed in 10 mM of NaHCO<sub>3</sub> at pH 9.2 for incubation at 4°C overnight. After blocking in 1 ml of TBS/6% BSA for 4 hours at 4°C the beads were incubated overnight with hIL-6 at 4°C. The beads were twice subjected to washing with 2 ml of TBST followed by incubation for 1 hour in 1 ml of TBST/0.1% BSA at 20°C. Subsequently the phages were eluted in 500 $\mu$ l of 100 mM glycine HCl pH 2.2 and the eluate was neutralised with 3M Tris HCl pH 8.9. The phages bound to the antibodies can be detected by PCR, as described in 30    the invention.

EXAMPLE 4

35    Method for detection of the soluble form of the human IL-6 receptor within a culture of engineered CHO cells

A method is described in which the human IL-6

- 16 -

receptor, expressed in engineered ovary carcinoma cells, is detected according to the method described in the present invention and if possible quantified using phages capable of expressing IL-6 or superantagonists of IL-6.

5        A CHO cell line (CsRh14) is capable of secreting a soluble form of the interleukin 6 receptor (ref). Using 100  $\mu$ l of tosyl-activated Dynabeads M450 (unipath) a concentrated form was prepared, using a magnetic particle concentrator, washed with 50 mM sodium borate at pH 9.5  
10      and incubating for 24 hours at 25°C in 400  $\mu$ l of the same buffer containing 15 $\mu$ g of monoclonal anti-hIL-6R $\alpha$  antibodies. After saturating passage in TBS/0.1%BSA for 12 hours at 4°C, the beads were incubated for 4 hours at 25°C with 400  $\mu$ l of conditioned medium containing no  
15      serum, obtained from the line CsRh14, containing 250 ng of shIL-6R $\alpha$ . After washing several times the beads to which the shIL-6R $\alpha$  had been bound were incubated with the phages expressing hIL-6 (in a ratio of 1:4) for 16 hours at 4°C. The reaction volume was brought up to 1 ml by  
20      adding an appropriate amount of TBS/0.1%BSA. The beads were washed 3 times with 1 ml of TBST and the phages eluted in 400 ml of 100 mM citrate buffer at pH 3.2. After neutralisation with 3M Tris CHl pH 8.9 the bound  
25      phages were detected by PCR amplification, in accordance with the nature of the present invention.

- 17 -

Bibliography

1. V. Ruzicka, W. Marz, A. Russ and W. Gross: 1993 Science 260, 698-699.
2. T. Sano, C.L. Smith, C.R. Cantor: 1992 Science 258, 5 120-122.
3. H. Zhou, R.J. Fischer and T.S. Papas: 1993 Nucl. Ac. Res. 21, 6038-3039.
4. D.E. Birch, L. Kolmodin, J. Wong, G.A. Zangenberg and M.A. Zoccoli: 1996 Nature 381, 445-446.
- 10 5. J. Cheng, M.A. Shoffner, G.E. Hvichia, L.J. Kricka and P. Wilding: 1996 Nucl. Ac. Res. 24, 380-385.
6. G.J. Nuovo PCR in situ hybridization, Protocols and applications. Rower Press 1994.

CLAIMS

1. A method for detection of the presence of molecules of interest in biological samples, comprising a combination of the following operations:

5 a) immobilising the molecules of interest without destroying the ability to interact with the molecules exposed on the surfaces of the phage;

10 b) causing a molecule of interest, immobilised as above, to bind specifically with at least one of the recombinant filamentous bacteriophages, which have internally a single-strand DNA molecule whose sequence is at least partially known, and exposing on the surfaces of the capsid at least one molecule capable of binding specifically to at least one molecule of interest present 15 in the biological sample;

c) separating the molecule-bacteriophage complexes obtained in this manner from the reaction mixture;

d) washing to remove the complexes generated by non-specific interaction between molecule and bacteriophage;

20 e) adding the reagents to carry out the operation described under g) below;

f) lysating the proteins forming the protein capsid of the bacteriophages selected in this way;

25 g) amplifying the DNA obtained as above by polymerase chain reaction (PCR);

h) detecting the DNA amplified as above.

2. The method for detection of the presence of molecules of interest in biological samples according to claim 1, in which the operation indicated under f) is performed at a temperature at which denaturation of the DNA takes place, which forms a step of the subsequent operation indicated under g), is immediately followed by lysis of the capsid proteins, and takes place at the same temperature, thus achieving a "Hot Start" for the PCR.

35 3. The method for detection of the presence of molecules of interest in biological samples according to any one of the claims 1 or 2, in which the molecules of

interest are antibodies.

4. The method for detection of the presence of molecules of interest in biological samples according to any one of claims 1 to 3, in which the molecules of interest are immobilised on a solid phase.

5. The method for detection of the presence of molecules of interest in biological samples according to claim 4, in which immobilisation on the solid phase of the molecules of interest takes place by passive 10 adsorption.

15. The method for detection of the presence of molecules of interest in biological samples according to claim 4, in which immobilisation of the molecules of interest on the solid phase takes place by the use of antibodies specific to the molecules themselves.

7. The method for detection of the presence of molecules of interest in biological samples according to claim 3, in which immobilisation of the molecules in the solid phase takes place by use of bacteria or of at least 20 one of the bacterial proteins, selected from the group comprising protein A of *Staphylococcus Aureus*, protein G of group C *Streptococci* and any other bacterial protein capable of binding animal immunoglobulins.

25. The method for detection of the presence of molecules of interest in biological samples according to any one of claims 1 to 7, in which the bacteriophages exhibit on the surfaces of the capsid viral antigens, parts thereof or oligopeptides capable of mimicking the effects of their presence in the biological fluids under 30 examination.

35. The method for detection of the presence of molecules of interest in biological samples according to any one of claims 1 to 7, in which the bacteriophages exhibit on the surfaces of the capsid auto-antigens, parts thereof or oligopeptides capable of mimicking the effects of their presence in the biological fluids under examination.

- 20 -

10. The method for detection of the presence of molecules of interest in biological samples according to any one of claims 1 to 7, in which the bacteriophages exhibit on the surfaces of the capsid allergens, parts thereof or oligopeptides capable of mimicking the effects of their presence in the biological fluids under examination.

11. The method for detection of the presence of molecules of interest in biological samples according to any one of claims 1 to 7, in which the bacteriophages exhibit on the surfaces of the capsid cell membrane receptors, parts of said receptors or oligopeptides capable of mimicking the biological activity thereof.

12. The method for detection of the presence of molecules of interest in biological samples according to any one of claims 1 to 7, in which the bacteriophages exhibit on the surfaces of the capsid specific cell membrane receptors or peptides deriving therefrom.

13. The method for detection of the presence of molecules of interest in biological samples according to any one of claims 1 to 7, in which the bacteriophages exhibit on the surfaces of the capsid ligands of amino acid nature whose receptor is presumed to be present in the fluids to be tested.

14. The method for detection of the presence of molecules of interest in biological samples according to any one of claims 1 to 7, in which the bacteriophages exhibit jointly on the surfaces of the capsid the molecules described in claims 11, 12, 13, 14, 15, and/or 16.

15. The method for detection of the presence of molecules of interest in biological samples, as described, exemplified and claimed above.

- 1/2 -




Fig. 1




Fig. 2

- 2/2 -




Fig. 3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/IT 98/00130

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 6 C12Q1/68 C12Q1/70 G01N33/566 G01N33/58

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 627 488 A (ANGELETTI P IST RICHERCHE B10) 7 December 1994 see examples 2-4 ----	1-15
Y	WO 94 26886 A (ANGELETTI P IST RICHERCHE B10 ;FELICI FRANCO (IT); LUZZAGO ALESSAN) 24 November 1994 see page 1-5; examples 4,5 ----	1-15
Y	WO 85 04189 A (TEODORESCU MARIUS C ;GASPAR ALEXANDRE (FR)) 26 September 1985 see the whole document ----	1-15
Y	WO 93 17129 A (JUDKINS PAUL W ;BIRCH RUTH E (US)) 2 September 1993 see the whole document ----	1-15
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 August 1998

Date of mailing of the international search report

03/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Osborne, H

## INTERNATIONAL SEARCH REPORT

national Application No

PCT/IT 98/00130

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 15229 A (DU PONT) 5 August 1993 see claims 1-28; figure 1 ----	1-15
Y	EP 0 544 212 A (NISSHIN FLOUR MILLING CO) 2 June 1993 see the whole document ----	1-15
A	EP 0 366 448 A (GEN HOSPITAL CORP) 2 May 1990 see the whole document ----	1
A	WO 87 06270 A (SALK INST FOR BIOLOGICAL STUDI ;UNIV COLUMBIA (US)) 22 October 1987 see the whole document -----	1

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/IT 98/00130

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0627488	A 07-12-1994	IT 1261693	B	29-05-1996
WO 9426886	A 24-11-1994	IT 1270939	B	26-05-1997
		AU 685121	B	15-01-1998
		AU 6806994	A	12-12-1994
		BR 9406595	A	02-01-1996
		CA 2160486	A	24-11-1994
		CN 1122613	A	15-05-1996
		EP 0698091	A	28-02-1996
		JP 8506493	T	16-07-1996
WO 8504189	A 26-09-1985	DE 3590116	T	19-02-1987
		EP 0175761	A	02-04-1986
		GB 2181542	A	23-04-1987
		JP 61501489	T	24-07-1986
		NL 8520062	T	03-02-1986
		SE 8505458	A	19-11-1985
		US 4797363	A	10-01-1989
WO 9317129	A 02-09-1993	AU 3776493	A	13-09-1993
WO 9315229	A 05-08-1993	AU 3618593	A	01-09-1993
		CA 2129444	A	05-08-1993
		EP 0625211	A	23-11-1994
		JP 7505765	T	29-06-1995
EP 0544212	A 02-06-1993	JP 5149949	A	15-06-1993
EP 0366448	A 02-05-1990	US 5077192	A	31-12-1991
		AT 141651	T	15-09-1996
		DE 68926991	D	26-09-1996
		DE 68926991	T	23-01-1997
		ES 2091765	T	16-11-1996
		IE 76455	B	22-10-1997
		JP 2257899	A	18-10-1990
		US 5534406	A	09-07-1996
WO 8706270	A 22-10-1987	US 4957858	A	18-09-1990
		AT 105870	T	15-06-1994
		AU 600942	B	30-08-1990

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/IT 98/00130

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8706270	A	AU 7306887 A	09-11-1987
		DE 3789849 D	23-06-1994
		DE 3789849 T	01-09-1994
		EP 0266399 A	11-05-1988
		JP 1500005 T	12-01-1989
		JP 2710159 B	10-02-1998
		US 5503979 A	02-04-1996
		US 5620851 A	15-04-1997
		US 5356774 A	18-10-1994
		US 5364760 A	15-11-1994